Lb Pharmaceuticals (LBRX) Other Accumulated Expenses (2024 - 2026)

Lb Pharmaceuticals' Other Accumulated Expenses history runs 3 years deep, the most recent figure standing at $132000.0 for Q1 2026.

• On a quarterly basis, Other Accumulated Expenses changed N/A year-over-year to $132000.0 in Q1 2026; TTM through Mar 2026 was $132000.0, a N/A change from a year earlier, with the FY2025 full-year figure at $267000.0, up 17.11% from the prior year.
• Other Accumulated Expenses fell to $132000.0 in Q1 2026 per LBRX's latest filing, from $267000.0 in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $267000.0 in Q4 2025 and bottomed at $101000.0 in Q3 2025.
• The 3-year median for Other Accumulated Expenses is $180000.0 (2024), against an average of $182000.0.
• Biggest YoY gain for Other Accumulated Expenses was 17.11% in 2025; the steepest drop was 17.11% in 2025.
• Year by year, Other Accumulated Expenses stood at $228000.0 in 2024, then gained by 17.11% to $267000.0 in 2025, then sank by 50.56% to $132000.0 in 2026.
• Per Business Quant, the three latest LBRX Other Accumulated Expenses figures stand at $132000.0 (Q1 2026), $267000.0 (Q4 2025), and $101000.0 (Q3 2025).